Hormonal
Exogenous administration of Peptide YY (PYY) reduces appetite and food consumption by approximately 30% in both lean and obese humans, primarily through inhibition of gut motility and hypothalamic signaling.
Your gut produces a hormone called PYY to tell your brain you are full. In obesity, this signal is often weaker. While injecting PYY works in studies, it is not a standalone cure. Focus on foods that naturally stimulate PYY release (like those reaching the distal small bowel) and respect the satiety signals your body sends, as relying on a single 'magic bullet' hormone therapy is unlikely to succeed long-term.
The investigators found that a single infusion of PYY, as compared with an infusion of saline, reduced appetite and food consumption by approximately 30 percent at an all-you-want-to-eat buffet lunch provided two hours after the infusion.
Why this rating
Based on a specific human study (Batterham et al.) cited in a high-impact review, showing clear acute effects, though long-term efficacy is noted as uncertain.
Source
To Eat or Not to Eat — How the Gut Talks to the Brain
Judith Körner et al. · New England Journal of Medicine · 2003
DOI 10.1056/nejmp038114
More from this paper
- Successful long-term weight loss maintenance likely requires targeting multiple redundant hormonal systems simultaneously rather than a single molecule.Strong
- Obese individuals exhibit a diminished endogenous postprandial Peptide YY (PYY) response compared to lean individuals, despite consuming more calories.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →